Serum p-cresyl sulfate predicts cardiovascular disease and mortality in elderly hemodialysis patients

Archives of Medical Science

Volumn 9, Issue 4, 2013, Pages 662-668

  Lin, Cheng Jui ^a,b,c   Chuang, Chih Kuang ^a,c,d   Jayakumar, Thanasekaran ^a,e   Liu, Hsuan Liang ^c   Pan, Chi Feng ^a,c   Wang, Tuen Jen ^a   Chen, Han Hsiang ^a,b   Wu, Chih Jen ^a,b,e  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^c NATIONAL TAIPEI UNIVERSITY OF TECHNOLOGY   (Taiwan)

^d FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cardiovascular disease; Hemodialysis; Indoxyl sulfate; Mortality; P cresyl sulfate

Indexed keywords

4 CRESYL SULFATE; INDICAN; PROTEIN DERIVATIVE; TOXIN; UNCLASSIFIED DRUG;

AGED; AGING; ARTICLE; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL;

EID: 84883329081     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2013.36901     Document Type: Article

References (27)

1. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9: S16-23.
2. Chauveau P, Combe C, Laville M, et al. Factors influencing survival in hemodialysis patients aged older than 75 years: 5-year outcome study. Am J Kidney Dis 2001; 37: 997-1003.
3. Joly D, Anglicheau D, Alberti C, et al. Octogenarians reaching endstage renal disease: Cohort study of decisionmaking and clinical outcomes. J Am Soc Nephrol 2003; 14: 1012-21.
4. Kurella M, Covinsky KE, Collins AJ, et al. Octogenarians and nonagenarians starting dialysis in the United States. Ann Intern Med 2007; 146: 177-83.
5. Couchoud C, Labeeuw M, Moranne O, et al. A clinical score to predict 6-month prognosis in elderly patients starting dialysis for end-stage renal disease. Nephrol Dial Transplant 2009; 24: 1553-61.
6. Raff AC, Meyer TW, Hostetter TH. New insights into uremic toxicity. Curr Opin Nephrol Hypertens 2008; 17: 560-5.
7. Meyer TW, Hostetter TH. Uremia. N Engl J Med 2007; 357: 1316-25.
8. Meijers BK, De Loor H, Bammens B, et al. p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 1932-8.
9. Vanholder R, Meert N, Schepers E, et al. Review on uraemic solutes II-variability in reported concentrations: Causes and consequences. Nephrol Dial Transplant 2007; 22: 3115-21.
10. Martinez AW, Recht NS, Hostetter TH, et al. Removal of P-cresol sulfate by hemodialysis. J Am Soc Nephrol 2005; 16: 3430-6.
11. Meijers BK, Van Kerckhoven S, Verbeke K, et al. The uremic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis 2009; 54: 891-901.
12. Liabeuf S, Barreto DV, Barreto FC, et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 2010; 25: 1183-91.
13. Bammens B, Evenepoel P, Keuleers H, et al. Free serum concentrations of the protein-bound retention solute pcresol predicts mortality in hemodialysis patients. Kidney Int 2006; 69: 1081-7.
14. Barreto FC, Barreto DV, Liabeuf S, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4: 1551-8.
15. Lin CJ, Wu CJ, Pan CF, et al. Serum protein-bound uraemic toxins and clinical outcomes in haemodialysis patients. Nephrol Dial Transplant 2010; 25: 3693-700.
16. Vanholder R, Massy Z, Argiles A, et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-56.
17. Wu IW, Hsu KH, Lee CC, et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant 2010; 26: 938-47.
18. Meijers BK, Claes K, Bammens B, et al. p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol 2010; 5: 1182-9.
19. Meijers BK, Bammens B, de Moor B, et al. Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 2008; 73: 1174-80.
20. Vanholder R, De Smet R, Waterloos MA, et al. Mechanisms of uraemic inhibition of phagocyte reactive species production: Characterization of the role of p-cresol. Kidney Int 1995; 47: 510-7.
21. Dou L, Cerini C, Brunet P, et al. P-cresol, a uraemic toxin, decreases endothelial cell response to inflammatory cytokines. Kidney Int 2002; 62: 1999-2009.
22. De Smet R, Van Kaer J, Van Vlem B, et al. Toxicity of free p-cresol: A prospective and cross-sectional analysis. Clin Chem 2003; 49: 470-8.
23. De Smet R, David F, Sandra P, et al. A sensitive HPLC method for the quantification of free and total p-cresol in patients with chronic renal failure. Clin Chim Acta 1998; 278: 1-21.
24. Vanholder R, Bammens B, de Loor H, et al. Warning: The unfortunate end of p-cresol as a uraemic toxin. Nephrol Dial Transplant 2011; 26: 1464-7.
25. Schepers E, Meert N, Glorieux G, et al. P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant 2007; 22: 592-6.
26. Niwa T, Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 1994; 124: 96-104.
27. Miyazaki T, Ise M, Hirata M, et al. Indoxyl sulfate stimulates renal synthesis of transforming growth factorbeta 1 and progression of renal failure. Kidney Int Suppl 1997; 63: S211-4.